Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11320359 | 0.84 | GNG2 (0.53) | RAB9ANPC1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL12284991 | 0.82 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2EPHX2TSHR | |
| SCHEMBL2751372 | 0.80 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2EPHX2TSHR | |
| SCHEMBL27795716 | 0.79 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2EPHX2TSHR | |
| SCHEMBL18735757 | 0.79 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2EPHX2TSHR | |
| SCHEMBL1504611 | 0.78 | NAMPT (0.56) | RAB9ANPC1SMN1; SMN2HTTGAA | |
| SCHEMBL1504546 | 0.77 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2EPHX2TSHR | |
| SCHEMBL12407204 | 0.77 | EPHX1 (0.84) | RAB9ANPC1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL21750955 | 0.77 | EPHX1 (0.84) | RAB9ANPC1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL2855474 | 0.77 | TDP1 (0.52) | RAB9ANPC1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2155683-B8 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2155683-A2 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | Astellas Pharma Inc. (JP) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140066-A2 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | RAB9A 1797/4885NPC1 4090/4885SMN1; SMN2 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.